24/04/2014 13:27:33 Free Membership Login

Allergan 1Q Profit Rose 45% On Stronger Specialty Drug Sales

Date : 05/02/2012 @ 10:05AM
Source : Dow Jones News
Stock : Allergan, (AGN)
Quote : 165.4875  -0.1625 (-0.10%) @ 1:12PM
Allergan share price Chart

Allergan 1Q Profit Rose 45% On Stronger Specialty Drug Sales

Allergan (NYSE:AGN)
Historical Stock Chart

2 Years : From Apr 2012 to Apr 2014

Click Here for more Allergan Charts.

Allergan Inc.'s (AGN) first-quarter earnings rose 45% as the maker of Botox and medical devices reported double-digit sales growth at its specialty pharmaceuticals business.

The company projected second-quarter results below analysts' expectations, with earnings of $1.04 to $1.06 a share on revenue of $1.45 billion to $1.5 billion. Analysts polled by Thomson Reuters most recently expected $1.08 and $1.51 billion, respectively.

Allergan has seen its revenue grow for more than two years, aided by surging sales of the wrinkle-fighting drug Botox, which has also won approval to treat various medical issues. The company continues to seek approvals for new uses of its best-selling drug, such as the treatment of overactive bladder and osteoporosis.

Like many pharmaceutical companies, Allergan has been expanding its pipeline lately, such as its acquisition of Vicept Therapeutics Inc.--the developer of a cream to treat rosacea--and a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue--were up nearly 11%, and roughly 12% excluding currency fluctuations. Botox sales were up 9.4% and eye-care pharmaceuticals sales grew 10%.

Its medical devices segment--which includes breast implants and the Lap-Band System for obesity--reported sales edged up 0.8%, or 2% excluding currency impacts.

Allergan reported a profit of $229.8 million, or 74 cents a share, up from $158.3 million, or 51 cents a share, a year earlier. Excluding acquisition and restructuring charges and other items, earnings were up at 86 cents from 77 cents.

Revenue increased 9.5% to $1.39 billion. Allergan in February expected earnings of 84 cents to 86 cents a share on revenue of $1.34 billion to $1.39 billion.

Operating margin rose to 25.5% from 19.5%.

Shares of Allergan, which backed its 2012 guidance, closed Tuesday at $96.39 and were inactive premarket. Through Tuesday's close, the stock is up 9.9% this year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com



NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us 140424 13:27